188 related articles for article (PubMed ID: 32394283)
1. A Multi-Ligand Imaging Study Exploring GABAergic Receptor Expression and Inflammation in Multiple Sclerosis.
Kang Y; Rúa SMH; Kaunzner UW; Perumal J; Nealon N; Qu W; Kothari PJ; Vartanian T; Kuceyeski A; Gauthier SA
Mol Imaging Biol; 2020 Dec; 22(6):1600-1608. PubMed ID: 32394283
[TBL] [Abstract][Full Text] [Related]
2. The neuronal component of gray matter damage in multiple sclerosis: A [(11) C]flumazenil positron emission tomography study.
Freeman L; Garcia-Lorenzo D; Bottin L; Leroy C; Louapre C; Bodini B; Papeix C; Assouad R; Granger B; Tourbah A; Dollé F; Lubetzki C; Bottlaender M; Stankoff B
Ann Neurol; 2015 Oct; 78(4):554-67. PubMed ID: 26292991
[TBL] [Abstract][Full Text] [Related]
3. GABA
Kessler M; Mamach M; Beutelmann R; Lukacevic M; Eilert S; Bascuñana P; Fasel A; Bengel FM; Bankstahl JP; Ross TL; Klump GM; Berding G
Mol Imaging Biol; 2020 Apr; 22(2):335-347. PubMed ID: 31102039
[TBL] [Abstract][Full Text] [Related]
4. In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand ¹¹C-PK11195.
Rissanen E; Tuisku J; Rokka J; Paavilainen T; Parkkola R; Rinne JO; Airas L
J Nucl Med; 2014 Jun; 55(6):939-44. PubMed ID: 24711650
[TBL] [Abstract][Full Text] [Related]
5. Innate immune cells and myelin profile in multiple sclerosis: a multi-tracer PET/MR study.
Pitombeira MS; Koole M; Campanholo KR; Souza AM; Duran FLS; Solla DJF; Mendes MF; Pereira SLA; Rimkus CM; Busatto GF; Callegaro D; Buchpiguel CA; de Paula Faria D
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4551-4566. PubMed ID: 35838758
[TBL] [Abstract][Full Text] [Related]
6. In vivo measurement of hippocampal GABAA/cBZR density with [18F]-flumazenil PET for the study of disease progression in an animal model of temporal lobe epilepsy.
Vivash L; Gregoire MC; Bouilleret V; Berard A; Wimberley C; Binns D; Roselt P; Katsifis A; Myers DE; Hicks RJ; O'Brien TJ; Dedeurwaerdere S
PLoS One; 2014; 9(1):e86722. PubMed ID: 24466212
[TBL] [Abstract][Full Text] [Related]
7. Neuroinflammatory component of gray matter pathology in multiple sclerosis.
Herranz E; Giannì C; Louapre C; Treaba CA; Govindarajan ST; Ouellette R; Loggia ML; Sloane JA; Madigan N; Izquierdo-Garcia D; Ward N; Mangeat G; Granberg T; Klawiter EC; Catana C; Hooker JM; Taylor N; Ionete C; Kinkel RP; Mainero C
Ann Neurol; 2016 Nov; 80(5):776-790. PubMed ID: 27686563
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal change in TSPO PET imaging in progressive multiple sclerosis.
Kang Y; Pandya S; Zinger N; Michaelson N; Gauthier SA
Ann Clin Transl Neurol; 2021 Aug; 8(8):1755-1759. PubMed ID: 34310086
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with (18)F-PBR111 PET.
Colasanti A; Guo Q; Muhlert N; Giannetti P; Onega M; Newbould RD; Ciccarelli O; Rison S; Thomas C; Nicholas R; Muraro PA; Malik O; Owen DR; Piccini P; Gunn RN; Rabiner EA; Matthews PM
J Nucl Med; 2014 Jul; 55(7):1112-8. PubMed ID: 24904112
[TBL] [Abstract][Full Text] [Related]
10. 18F-flumazenil: a γ-aminobutyric acid A-specific PET radiotracer for the localization of drug-resistant temporal lobe epilepsy.
Vivash L; Gregoire MC; Lau EW; Ware RE; Binns D; Roselt P; Bouilleret V; Myers DE; Cook MJ; Hicks RJ; O'Brien TJ
J Nucl Med; 2013 Aug; 54(8):1270-7. PubMed ID: 23857513
[TBL] [Abstract][Full Text] [Related]
11. PET measurement of "GABA shift" in the rat brain: A preclinical application of bolus plus constant infusion paradigm of [
Kim W; Park HS; Moon BS; Lee BC; Kim SE
Nucl Med Biol; 2017 Feb; 45():30-34. PubMed ID: 27886620
[TBL] [Abstract][Full Text] [Related]
12. Decreased GABA-A binding on FMZ-PET in succinic semialdehyde dehydrogenase deficiency.
Pearl PL; Gibson KM; Quezado Z; Dustin I; Taylor J; Trzcinski S; Schreiber J; Forester K; Reeves-Tyer P; Liew C; Shamim S; Herscovitch P; Carson R; Butman J; Jakobs C; Theodore W
Neurology; 2009 Aug; 73(6):423-9. PubMed ID: 19667317
[TBL] [Abstract][Full Text] [Related]
13. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis.
Sucksdorff M; Matilainen M; Tuisku J; Polvinen E; Vuorimaa A; Rokka J; Nylund M; Rissanen E; Airas L
Brain; 2020 Dec; 143(11):3318-3330. PubMed ID: 33006604
[TBL] [Abstract][Full Text] [Related]
14. Where in-vivo imaging meets cytoarchitectonics: the relationship between cortical thickness and neuronal density measured with high-resolution [18F]flumazenil-PET.
la Fougère C; Grant S; Kostikov A; Schirrmacher R; Gravel P; Schipper HM; Reader A; Evans A; Thiel A
Neuroimage; 2011 Jun; 56(3):951-60. PubMed ID: 21073964
[TBL] [Abstract][Full Text] [Related]
15. Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results.
Klumpers UM; Veltman DJ; Drent ML; Boellaard R; Comans EF; Meynen G; Lammertsma AA; Hoogendijk WJ
Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):565-74. PubMed ID: 19890631
[TBL] [Abstract][Full Text] [Related]
16. Advanced [(18)F]FDG and [(11)C]flumazenil PET analysis for individual outcome prediction after temporal lobe epilepsy surgery for hippocampal sclerosis.
Yankam Njiwa J; Gray KR; Costes N; Mauguiere F; Ryvlin P; Hammers A
Neuroimage Clin; 2015; 7():122-31. PubMed ID: 25610774
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two different methods of image analysis for the assessment of microglial activation in patients with multiple sclerosis using (R)-[N-methyl-carbon-11]PK11195.
Kang Y; Schlyer D; Kaunzner UW; Kuceyeski A; Kothari PJ; Gauthier SA
PLoS One; 2018; 13(8):e0201289. PubMed ID: 30091993
[TBL] [Abstract][Full Text] [Related]
18. Changes in GABAA receptor properties in amygdala kindled animals: in vivo studies using [11C]flumazenil and positron emission tomography.
Liefaard LC; Ploeger BA; Molthoff CF; de Jong HW; Dijkstra J; van der Weerd L; Lammertsma AA; Danhof M; Voskuyl RA
Epilepsia; 2009 Jan; 50(1):88-98. PubMed ID: 18727682
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Performance of Positron Emission Tomography for the Presurgical Evaluation of Patients with Non-lesional Intractable Partial Epilepsy: Comparison among 18F-FDG, 11C-Flumazenil, and 11C-Flumazenil Binding Potential Imaging Using Statistical Imaging Analysis.
Komoto D; Iida K; Higaki T; Kaichi Y; Takauchi K; Arihiro K; Kakita A; Hirokawa Y; Awai K
Hiroshima J Med Sci; 2015 Dec; 64(4):51-7. PubMed ID: 26964154
[TBL] [Abstract][Full Text] [Related]
20. Abnormalities of grey and white matter [11C]flumazenil binding in temporal lobe epilepsy with normal MRI.
Hammers A; Koepp MJ; Hurlemann R; Thom M; Richardson MP; Brooks DJ; Duncan JS
Brain; 2002 Oct; 125(Pt 10):2257-71. PubMed ID: 12244083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
